Diagnostic and therapeutic aspects of β1-adrenergic receptor autoantibodies in human heart disease

Autoimmunity Reviews

Volumn 13, Issue 9, 2014, Pages 954-962

  Bornholz, Beatrice ^a   Roggenbuck, Dirk ^b   Jahns, Roland ^c   Boege, Fritz ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b BRANDENBURG UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Autoantibodies; Beta1 adrenergic receptor; Cardiomyopathy; Diagnostic tests; Heart failure; Targeted therapy

Indexed keywords

AUTOANTIBODY; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G3; UNCLASSIFIED DRUG;

APHERESIS; AUTOIMMUNITY; BETA ADRENERGIC STIMULATION; CELL ASSAY; CONFORMATIONAL TRANSITION; CONGESTIVE CARDIOMYOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL ABSORPTION; HEART DISEASE; HUMAN; IMMUNE APHERESIS; IMMUNOASSAY; NONHUMAN; PROTEIN CONFORMATION; PROTEIN FUNCTION; REVIEW; WESTERN BLOTTING; X RAY DIFFRACTION; ANIMAL; HEART DISEASES; IMMUNOLOGY; PROTEIN TRANSPORT;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; HEART DISEASES; HUMANS; PROTEIN TRANSPORT; RECEPTORS, ADRENERGIC, BETA-1;

EID: 84922539950     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.08.021     Document Type: Review

References (97)

1. Lytton S.D., Kahaly G.J. Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev 2010, 10:116-122.
2. Zophel K., Roggenbuck D., Schott M. Clinical review about TRAb assay's history. Autoimmun Rev 2010, 9:695-700.
3. Wallukat G., Schimke I. Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin Immunopathol 2014, 36:351-363.
4. Maron B.J., Towbin J.A., Thiene G., Antzelevitch C., Corrado D., Arnett D., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006, 113:1807-1816.
5. Jahns R., Boivin V., Lohse M.J. Beta(1)-adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc Med 2006, 16:20-24.
6. Stork S., Boivin V., Horf R., Hein L., Lohse M.J., Angermann C.E., et al. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 2006, 152:697-704.
7. Dandel M., Wallukat G., Potapov E., Hetzer R. Role of beta(1)-adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy. Immunobiology 2011, 217:511-520.
8. Jahns R., Boivin V., Siegmund C., Inselmann G., Lohse M.J., Boege F. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999, 99:649-654.
9. Buvall L., Bollano E., Chen J., Shultze W., Fu M. Phenotype of early cardiomyopathic changes induced by active immunization of rats with a synthetic peptide corresponding to the second extracellular loop of the human beta-adrenergic receptor. Clin Exp Immunol 2006, 143:209-215.
10. Jahns R., Boivin V., Hein L., Triebel S., Angermann C.E., Ertl G., et al. Direct evidence for a beta(1)-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004, 113:1419-1429.
11. Fukuda Y., Miyoshi S., Tanimoto K., Oota K., Fujikura K., Iwata M., et al. Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces early afterdepolarization and decreases in K-channel density in rabbits. J Am Coll Cardiol 2004, 43:1090-1100.
12. Matsui S., Fu M.L., Hayase M., Katsuda S., Yamaguchi N., Teraoka K., et al. Active immunization of combined beta1-adrenoceptor and M2-muscarinic receptor peptides induces cardiac hypertrophy in rabbits. J Card Fail 1999, 5:246-254.
13. Jane-wit D., Altuntas C.Z., Johnson J.M., Yong S., Wickley P.J., Clark P., et al. Beta 1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation 2007, 116:399-410.
14. Zuo L., Bao H., Tian J., Wang X., Zhang S., He Z., et al. Long-term active immunization with a synthetic peptide corresponding to the second extracellular loop of beta(1)-adrenoceptor induces both morphological and functional cardiomyopathic changes in rats. Int J Cardiol 2011, 149:89-94.
15. Jahns R., Boivin V., Siegmund C., Boege F., Lohse M.J., Inselmann G. Activating beta-1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease. J Am Coll Cardiol 1999, 34:1545-1551.
16. Stavrakis S., Yu X., Patterson E., Huang S., Hamlett S.R., Chalmers L., et al. Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism. J Am Coll Cardiol 2009, 54:1309-1316.
17. Munoz-Saravia S.G., Haberland A., Wallukat G., Schimke I. Chronic Chagas' heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine. Heart Fail Rev 2012, 17:45-64.
18. Deubner N., Berliner D., Schlipp A., Gelbrich G., Caforio A.L., Felix S.B., et al. Cardiac beta1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study. Eur J Heart Fail 2010, 12:753-762.
19. Liu H.R., Zhao R.R., Zhi J.M., Wu B.W., Fu M.L. Screening of serum autoantibodies to cardiac beta1-adrenoceptors and M2-muscarinic acetylcholine receptors in 408 healthy subjects of varying ages. Autoimmunity 1999, 29:43-51.
20. Dandel M., Wallukat G., Englert A., Hetzer R. Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. Atherosclerosis Suppl 2013, 14:203-211.
21. Patel P.A., Hernandez A.F. Targeting anti-beta-1-adrenergic receptor antibodies for dilated cardiomyopathy. Eur J Heart Fail 2013, 15:724-729.
22. Jahns R., Schlipp A., Boivin V., Lohse M.J. Targeting receptor antibodies in immune cardiomyopathy. Semin Thromb Hemost 2010, 36:212-218.
23. Mobini R., Maschke H., Waagstein F. New insights into the pathogenesis of dilated cardiomyopathy: possible underlying autoimmune mechanisms and therapy. Autoimmun Rev 2004, 3:277-284.
24. Nikolaev V.O., Boivin V., Stork S., Angermann C.E., Ertl G., Lohse M.J., et al. A novel fluorescence method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol 2007, 50:423-431.
25. Tutor A.S., Penela P., Mayor F. Anti-beta1-adrenergic receptor autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells. Cardiovasc Res 2007, 76:51-60.
26. Stavrakis S., Kem D.C., Patterson E., Lozano P., Huang S., Szabo B., et al. Opposing cardiac effects of autoantibody activation of beta-adrenergic and M2 muscarinic receptors in cardiac-related diseases. Int J Cardiol 2011, 148:331-336.
27. Staudt A., Eichler P., Trimpert C., Felix S.B., Greinacher A. Fc(gamma) receptors IIa on cardiomyocytes and their potential functional relevance in dilated cardiomyopathy. J Am Coll Cardiol 2007, 49:1684-1692.
28. Magnusson Y., Marullo S., Hoyer S., Waagstein F., Andersson B., Vahlne A., et al. Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1990, 86:1658-1663.
29. Wallukat G., Wollenberger A., Morwinski R., Pitschner H.F. Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 1995, 27:397-406.
30. Fu L.X., Magnusson Y., Bergh C.H., Liljeqvist J.A., Waagstein F., Hjalmarson A., et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1993, 91:1964-1968.
31. Wallukat G., Munoz Saravia S.G., Haberland A., Bartel S., Araujo R., Valda G., et al. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon. Their potential impact for early risk assessment in asymptomatic Chagas' patients. J Am Coll Cardiol 2010, 55:463-468.
32. Herda L.R., Felix S.B., Boege F. Drug-like actions of autoantibodies against receptors of the autonomous nervous system and their impact on human heart function. Br J Pharmacol 2012, 166:847-857.
33. Sterin-Borda L., Cossio P.M., Gimeno M.F., Gimeno A.L., Diez C., Laguens R.P., et al. Effect of chagasic sera on the rat isolated atrial preparation: immunological, morphological and function aspects. Cardiovasc Res 1976, 10:613-622.
34. Magnusson Y., Wallukat G., Waagstein F., Hjalmarson A., Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation 1994, 89:2760-2767.
35. Magnusson Y., Hjalmarson A., Hoebeke J. Beta 1-adrenoceptor autoimmunity in cardiomyopathy. Int J Cardiol 1996, 54:137-141.
36. Cunha-Neto E., Teixeira P.C., Fonseca S.G., Bilate A.M., Kalil J. Myocardial gene and protein expression profiles after autoimmune injury in Chagas' disease cardiomyopathy. Autoimmun Rev 2011, 10:163-165.
37. Bornholz B., Weidtkamp-Peters S., Schmitmeier S., Seidel C.A., Herda L.R., Felix S.B., et al. Impact of human autoantibodies on beta1-adrenergic receptor conformation, activity, and internalization. Cardiovasc Res 2013, 97:472-480.
38. Christ T., Schindelhauer S., Wettwer E., Wallukat G., Ravens U. Interaction between autoantibodies against the beta1-adrenoceptor and isoprenaline in enhancing L-type Ca2+ current in rat ventricular myocytes. J Mol Cell Cardiol 2006, 41:716-723.
39. Holthoff H.P., Zeibig S., Boivin V., Bauer J., Lohse M.J., Kaab S., et al. Detection of anti beta1-AR auto-antibodies in heart failure by a cell-based competition ELISA. Circ Res 2012, 111:675-684.
40. Jahns R., Siegmund C., Jahns V., Reilander H., Maidhof A., Muller-Esterl W., et al. Probing human beta 1-and beta 2-adrenoceptors with domain-specific fusion protein antibodies. Eur J Pharmacol 1996, 316:111-121.
41. Matsui S., Larsson L., Hayase M., Katsuda S., Teraoka K., Kurihara T., et al. Specific removal of beta1-adrenoceptor autoantibodies by immunoabsorption in rabbits with autoimmune cardiomyopathy improved cardiac structure and function. J Mol Cell Cardiol 2006, 41:78-85.
42. Liu J., Mao W., Iwai C., Fukuoka S., Vulapalli R., Huang H., et al. Adoptive passive transfer of rabbit beta1-adrenoceptor peptide immune cardiomyopathy into the Rag2-/- mouse: participation of the ER stress. J Mol Cell Cardiol 2008, 44:304-314.
43. Matsui S., Fu M., Hayase M., Katsuda S., Yamaguchi N., Teraoka K., et al. Transfer of immune components from rabbit autoimmune cardiomyopathy into severe combined immunodeficiency (SCID) mice induces cardiomyopathic changes. Autoimmunity 2006, 39:121-128.
44. Matsui S., Persson M., Fu H.M., Hayase M., Katsuda S., Teraoka K., et al. Protective effect of bisoprolol on beta-1 adrenoceptor peptide-induced autoimmune myocardial damage in rabbits. Herz 2000, 25:267-270.
45. Haberland A., Wallukat G., Dahmen C., Kage A., Schimke I. Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies. Circ Res 2011, 109:986-992.
46. Munch G., Boivin-Jahns V., Holthoff H.P., Adler K., Lappo M., Truol S., et al. Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail 2012, 11:1230-1239.
47. Chiale P.A., Ferrari I., Mahler E., Vallazza M.A., Elizari M.V., Rosenbaum M.B., et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation 2001, 103:1765-1771.
48. Iwata M., Yoshikawa T., Baba A., Anzai T., Mitamura H., Ogawa S. Autoantibodies against the second extracellular loop of beta(1)-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001, 37:418-424.
49. Pei J., Li N., Chen J., Li X., Zhang Y., Wang Z., et al. The predictive values of beta1-adrenergic and M2 muscarinic receptor autoantibodies for sudden cardiac death in patients with chronic heart failure. Eur J Heart Fail 2012, 14:887-894.
50. Felix S.B., Staudt A., Landsberger M., Grosse Y., Stangl V., Spielhagen T., et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002, 39:646-652.
51. Ronspeck W., Brinckmann R., Egner R., Gebauer F., Winkler D., Jekow P., et al. Peptide based adsorbers for therapeutic immunoadsorption. Ther Apher Dial 2003, 7:91-97.
52. Wallukat G., Muller J., Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 2002, 347:1806.
53. Ma L.P., Premaratne G., Bollano E., Lindholm C., Fu M. Interleukin-6-deficient mice resist development of experimental autoimmune cardiomyopathy induced by immunization of beta1-adrenergic receptor. Int J Cardiol 2012, 155:20-25.
54. Levin M.J., Hoebeke J. Cross-talk between anti-beta1-adrenoceptor antibodies in dilated cardiomyopathy and Chagas' heart disease. Autoimmunity 2008, 41:429-433.
55. Lopez Bergami P., Gomez K.A., Levy G.V., Grippo V., Baldi A., Levin M.J. The beta1 adrenergic effects of antibodies against the C-terminal end of the ribosomal P2beta protein of Trypanosoma cruzi associate with a specific pattern of epitope recognition. Clin Exp Immunol 2005, 142:140-147.
56. Nussinovitch U., Shoenfeld Y. Intravenous immunoglobulin - indications and mechanisms in cardiovascular diseases. Autoimmun Rev 2008, 7:445-452.
57. Jahns R., Boivin V., Krapf T., Wallukat G., Boege F., Lohse M.J. Modulation of beta(1)-adrenoceptor activity by domain-specific antibodies and-heart failure-associated autoantibodies. J Am Coll Cardiol 2000, 36:1280-1287.
58. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
59. Rasmussen S.G., Devree B.T., Zou Y., Kruse A.C., Chung K.Y., Kobilka T.S., et al. Crystal structure of the beta(2) adrenergic receptor-Gs protein complex. Nature 2011, 477:549-555.
60. Bristow M.R., Gingurg R., Minobe W., Cubiciotti R.S., Sageman W.S., Lurie K., et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med 1982, 307:205-211.
61. Huang J., Chen S., Zhang J.J., Huang X.Y. Crystal structure of oligomeric beta1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat Struct Biol 2013, 20:419-425.
62. Lohse M.J. Molecular mechanisms of membrane receptor desensitization. Biochem Biophys Acta 1993, 1179:171-188.
63. Bristow M.R. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101:558-569.
64. Iwata M., Yoshikawa T., Baba A., Anzai T., Nakamura I., Wainai Y., et al. Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res 2001, 88:578-586.
65. Staudt Y., Mobini R., Fu M., Felix S.B., Kuhn J.P., Staudt A. Beta(1)-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharmacol 2003, 466:1-6.
66. Lefkowitz R.J., Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 2005, 308:512-517.
67. Del Corsso C., de Carvalho A.C., Martino H.F., Varanda W.A. Sera from patients with idiopathic dilated cardiomyopathy decrease ICa in cardiomyocytes isolated from rabbits. Am J Physiol Heart Circ Physiol 2004, 287:H1928-H1936.
68. Lavoie C., Mercier J.F., Salahpour A., Umapathy D., Breit A., Villeneuve L.R., et al. Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem 2002, 277:35402-35410.
69. Zhu W.Z., Chakir K., Zhang S., Yang D., Lavoie C., Bouvier M., et al. Heterodimerization of beta1-and beta2-adrenergic receptor subtypes optimizes beta-adrenergic modulation of cardiac contractility. Circ Res 2005, 97:244-251.
70. Schimke I., Muller J., Dandel M., Gremmels H.D., Bayer W., Wallukat B., et al. Reduced oxidative stress in parallel to improved cardiac performance one year after selective removal of anti-beta 1-adrenoreceptor autoantibodies in patients with idiopathic dilated cardiomyopathy: data of a preliminary study. J Clin Apher 2005, 20:137-142.
71. Caforio A.L., Vinci A., Iliceto S. Anti-heart autoantibodies in familial dilated cardiomyopathy. Autoimmunity 2008, 41:462-469.
72. Caforio A.L., Daliento L., Angelini A., Bottaro S., Vinci A., Dequal G., et al. Autoimmune myocarditis and dilated cardiomyopathy: focus on cardiac autoantibodies. Lupus 2005, 14:652-655.
73. Nitsche A., Kurth A., Dunkhorst A., Panke O., Sielaff H., Junge W., et al. One-step selection of Vaccinia virus-binding DNA aptamers by MonoLEX. BMC Biotechnol 2007, 7:48.
74. Haberland A., Wallukat G., Berg S., Schulz A.M., Freyse E.J., Vetter R., et al. Neutralization of pathogenic beta1-receptor autoantibodies by aptamers in vivo: the first successful proof of principle in spontaneously hypertensive rats. Mol Cell Biochem 2014, 393:177-180.
75. Port J.D., Bristow M.R. Aptamer therapy for heart failure?. Circ Res 2011, 109:982-983.
76. Jahns R., Boivin V., Hein L., Palm D., Nikolaev V.O., Müller J., et al. A new cyclic receptor-peptide prevents development of heart dilatation and failure induced by antibodies activating cardiac beta1-adrenergic receptors. Circulation 2005, 112(Suppl. II 5 (120)).
77. Tate K., Magnusson Y., Viguier M., Lengagne R., Hjalmarson A., Guillet J.G., et al. Epitope analysis of T- and B-cell response against the human beta 1-adrenoceptor. Biochimie 1994, 76:159-164.
78. Arndt-Maric R., Nagele H., Schewe G., Kromminga A. Are autoantibodies against the beta1-adrenergic receptor markers for dilated cardiomyopathy?. Clin Lab 2010, 56:519-526.
79. Roggenbuck D., Hiemann R., Bogdanos D., Reinhold D., Conrad K. Standardization of automated interpretation of immunofluorescence tests. Clin Chim Acta 2013, 421:168-169.
80. Hiemann R., Buttner T., Krieger T., Roggenbuck D., Sack U., Conrad K. Challenges of automated screening and differentiation of non-organ specific autoantibodies on HEp-2 cells. Autoimmun Rev 2009, 9:17-22.
81. Hekman M., Feder D., Keenan A.K., Gal A., Klein H.W., Pfeuffer T., et al. Reconstitution of beta-adrenergic receptor with components of adenylate cyclase. EMBO J 1984, 3:3339-3345.
82. Wallukat G., Nisson E. Anti beta(1)-adrenoceptor autoantibodies analyzed in spontaneously beating neonatal rat heart myocyte cultures - comparison of methods. Cell Dev Biol 2001, 37:175-176.
83. Nguemo F., Saric T., Pfannkuche K., Watzele M., Reppel M., Hescheler J. In vitro model for assessing arrhythmogenic properties of drugs based on high-resolution impedance measurements. Cell Physiol Biochem 2012, 29:819-832.
84. Dinger M.C., Beck-Sickinger A.G. The first reporter gene assay on living cells: green fluorescent protein as reporter gene for the investigation of Gi-protein coupled receptors. Mol Biotechnol 2002, 21:9-18.
85. Albanese C., Christin-Maitre S., Sluss P.M., Crowley W.F., Jameson J.L. Development of a bioassay for FSH using a recombinant human FSH receptor and a cAMP responsive luciferase reporter gene. Mol Cell Endocrinol 1994, 101:211-219.
86. Himmler A., Stratowa C., Czernilofsky A.P. Functional testing of human dopamine D1 and D5 receptors expressed in stable cAMP-responsive luciferase reporter cell lines. J Recept Res 1993, 13:79-94.
87. Fu M.L., Herlitz H., Wallukat G., Hilme E., Hedner T., Hoebeke J., et al. Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension. Lancet 1994, 344:1660-1663.
88. Luther H.P., Homuth V., Wallukat G. Alpha 1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension 1997, 29:678-682.
89. Wenzel K., Haase H., Wallukat G., Derer W., Bartel S., Homuth V., et al. Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension. PLoS One 2008, 3:e3742.
90. Wallukat G., Homuth V., Fischer T., Lindschau C., Horstkamp B., Jupner A., et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999, 103:945-952.
91. Ma G., Li Y., Zhang J., Liu H., Hou D., Zhu L., et al. Association between the presence of autoantibodies against adrenoreceptors and severe pre-eclampsia: a pilot study. PLoS One 2013, 8:e57983.
92. Dragun D., Muller D.N., Brasen J.H., Fritsche L., Nieminen-Kelha M., Dechend R., et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558-569.
93. Li H., Scherlag B.J., Kem D.C., Zillner C., Male S., Thirunavukkarasu S., et al. Atrial tachycardia provoked in the presence of activating autoantibodies to beta2-adrenergic receptor in the rabbit. Heart Rhythm 2013, 10:436-441.
94. Hong C.M., Zheng Q.S., Liu X.T., Shang F.J., Wang H.T., Jiang W.R. Effects of autoantibodies against M2 muscarinic acetylcholine receptors on rabbit atria in vivo. Cardiology 2009, 112:180-187.
95. Baba A., Yoshikawa T., Fukuda Y., Sugiyama T., Shimada M., Akaishi M., et al. Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J 2004, 25:1108-1115.
96. Li H., Zuccolo J., Kem D.C., Zillner C., Lee J., Smith K., et al. Implications of a vasodilatory human monoclonal autoantibody in postural hypotension. J Biol Chem 2013, 288:30734-30741.
97. Kohr D., Singh P., Tschernatsch M., Kaps M., Pouokam E., Diener M., et al. Autoimmunity against the beta(2) adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain 2011, 152:2690-2700.